Albeit, some clinical trials with SK2 inhibitors have been conducted on diffuse large B-cell lymphoma (DLBCL) (NCT02229981) and multiple myeloma (MM) (NCT02757326). Here, SPHK2 is linked to diffuse large B-cell lymphoma.